Abstract 1484O
Background
Risk assessment according to the AFIP/Miettinen classification and mutational profiling are major tools for patient management. However, the AFIP/Miettinen classification depends heavily on mitotic counts, which is laborious and sometimes inconsistent between pathologists. It has also been shown to be imperfect in stratifying patients. Molecular testing is costly and time consuming, therefore not systematically performed in all countries. New methods to improve risk and molecular predictions are hence crucial to improve the tailoring of adjuvant therapy.
Methods
We have built deep learning (DL) models on digitized H&E-stained whole slide images (WSI) to predict patients’ outcome and mutations. Models were trained with a cohort of 1233 GIST and validated on an independent cohort of 286 GIST.
Results
DL models outperformed the Miettinen classification for relapse-free-survival prediction in localized GIST without adjuvant Imatinib (C-index=0.83 in testing and 0.72 for independent validation). DL splitted Miettinen intermediate risk GIST into high/low risk groups(p value=2.1e-03). DL models achieved an area under the receiver operating characteristic curve (AUC) of 0.81, 0.91 and 0.71 for predicting mutations in KIT, PDGFRA and wild type respectively in testing and 0.84, 0.93 and 0.56 in independent validation. Notably, PDGFRA exon18 D842V mutation which is resistant to Imatinib, was predicted with an AUC of 0.87 and 0.90 in testing and independent validation, respectively. Additionally, novel histological criteria predictive of patients’ outcome and mutations were identified by reviewing the tiles selected by the models.
Conclusions
Our results strongly suggest that implementing DL with digitized WSI may represent a reproducible way to improve tailoring therapy and precision medicine for patients with GIST.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institut Bergonié. Bordeaux, France.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1482O - A phase III study comparing methotrexate (M), adriamycin (A) and cisplatin (P) with MAP + ifosfamide (MAP + IF) for the treatment of osteosarcoma: JCOG0905
Presenter: Hiroaki Hiraga
Session: Proffered Paper session: Sarcoma
Resources:
Abstract
Slides
Webcast
1483O - Results of a phase I/II combination regimen with ipilimumab (I), nivolumab (N) and trabectedin (T) as first line therapy for advanced leiomyosarcoma
Presenter: Erlinda Gordon
Session: Proffered Paper session: Sarcoma
Resources:
Abstract
Slides
Webcast
Invited Discussant 1482O and 1483O
Presenter: Kjetil Boye
Session: Proffered Paper session: Sarcoma
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session: Sarcoma
Resources:
Webcast
1485O - Percutaneous uterine needle biopsy with microscopic and array-CGH analyses in patients with suspicious myometrial tumors on MRI: A prospective study
Presenter: Jeremy SMADJA
Session: Proffered Paper session: Sarcoma
Resources:
Abstract
Slides
Webcast
Invited Discussant 1485O and 1484O
Presenter: Jakob Kather
Session: Proffered Paper session: Sarcoma
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session: Sarcoma
Resources:
Webcast